J Endod. 2017 May 3. pii: S0099-2399(17)30152-8. doi: 10.1016/j.joen.2017.01.037. [Epub ahead of print]
.
- 1
- Department
of Pediatric Dentistry, Faculty of Dentistry, Chulalongkorn University,
Bangkok, Thailand; Dental Biomaterials Science Program, Graduate
School, Chulalongkorn University, Bangkok, Thailand.
- 2
- Department of Pediatric Dentistry, Faculty of Dentistry, Chulalongkorn University, Bangkok, Thailand.
- 3
- Department of Chemistry, Faculty of Sciences, Chulalongkorn University, Bangkok, Thailand.
- 4
- Department of Surgery, Faculty of Veterinary Science, Chulalongkorn University, Bangkok, Thailand.
- 5
- Department of Pathology, Faculty of Veterinary Science, Chulalongkorn University, Bangkok, Thailand.
- 6
- Research Unit of Herbal Medicine,
Biomaterial and Material for Dental Treatment, Department of Anatomy,
Faculty of Dentistry, Chulalongkorn University, Bangkok, Thailand.
Electronic address: pthunyak@yahoo.com.
Abstract
INTRODUCTION:
This
study investigated the effects of acemannan, a polysaccharide from Aloe
vera, on human deciduous pulp cells in vitro and the response after
vital pulp therapy in dog deciduous teeth.
METHODS:
Human
primary dental pulpal cells were treated with acemannan in vitro and
evaluated for proliferation, alkaline phosphatase activity, type I
collagen, bone morphogenetic protein (BMP-2), BMP-4, vascular
endothelial growth factor, and dentin sialoprotein expression and
mineralization. Osteogenesis-related gene expression was analyzed by
complementary DNA microarray. Pulpal inflammation was induced in dog
teeth for 14 days. The inflamed pulp was removed, retaining the healthy
pulp. The teeth were randomly divided into 3 treatment groups:
acemannan, mineral trioxide aggregate, and formocresol. Sixty days
later, the teeth were extracted and evaluated histopathologically.
RESULTS:
Acemannan
significantly increased pulp cell proliferation, alkaline phosphatase,
type I collagen, BMP-2, BMP-4, vascular endothelial growth factor, and
dentin sialoprotein expression and mineralization approximately 1.4-,
1.6-, 1.6-, 5.5-, 2.6-, 3.8-, 1.8-, and 4.8-fold, respectively, compared
with control. In vivo, partial pulpotomy treatment using acemannan
generated outcomes similar to mineral trioxide aggregate treatment,
resulting in mineralized bridge formation with normal pulp tissue
without inflammation or pulp necrosis. In contrast, the formocresol
group demonstrated pulp inflammation without mineralized bridge
formation.
CONCLUSIONS:
Acemannan
is biocompatible with the dental pulp. Furthermore, acemannan
stimulated dentin regeneration in teeth with reversible pulpitis.
Copyright © 2017 American Association of Endodontists. Published by Elsevier Inc. All rights reserved.
KEYWORDS:
Acemannan; MTA; animal model; dentin regeneration; microarray; vital pulp therapy